Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals is a biopharmaceutical company leveraging breakthrough advances in synthetic chemistry. Tetraphase Pharmaceuticals is utilizing a dynamic drug engine targeting several important disease categories. The fight against antimicrobial resistance lies at the core of their mission as a company. It unites the company around a common goal and drives their determination to develop new antibiotics that can overcome the challenges posed by drug-resistant bacteria, ensuring effective treatments will be available in the future. Their efforts have yielded XERAVA™ (eravacycline), an antibacterial injection currently on the market, as well as several research compounds with potential for licensure.